Current Therapeutic Approaches for Early-Stage HER2-Positive Breast Cancer

Download this slideset with key data on optimal adjuvant therapy and extended adjuvant therapy for patients with early-stage HER2-positive breast cancer. Experts discuss how to identify which patients are most likely to benefit from the available treatment strategies.
Sara Hurvitz, MD, FACP
Hope S. Rugo, MD

Downloadable Slideset

Download these slides from our live meeting series on treatment strategies for HER2+ EBC to review the current clinical rational and most recent data on HER2-targeted for patients with early stage HER2+ breast cancer.

Sara Hurvitz, MD, FACP Hope S. Rugo, MD Released: April 25, 2019
Provided by Postgraduate Institute for Medicine
PIM Logo

Postgraduate Institute for Medicine
304 Inverness Way South, Suite 100
Englewood, CO 80112

Allison Hughes, CCMEP, Program Manager
(303) 799-1930
(303) 858-8842 (Fax)
ahughes@pimed.com
www.pimed.com

Supported by an educational grant from
Puma Biotechnology, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?